Published in Clin Infect Dis on May 26, 2016
High prevalence of human papillomaviruses in Ghanaian pregnant women. Med Microbiol Immunol (2016) 0.78
Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. Ther Adv Vaccines (2017) 0.75
Future prospects for new vaccines against sexually transmitted infections. Curr Opin Infect Dis (2016) 0.75
Human Vaccines & Immunotherapeutics: News. Hum Vaccin Immunother (2016) 0.75
Ecological validity of cost-effectiveness models of universal HPV vaccination: a protocol for a systematic review. Syst Rev (2017) 0.75
Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study. BMC Public Health (2016) 0.75
The epidemiologic status of gynecologic cancer in Thailand. J Gynecol Oncol (2016) 0.75
Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies. PLoS One (2017) 0.75
Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction. Vaccine (2017) 0.75
Human papillomavirus vaccination: the population impact. F1000Res (2017) 0.75
Health care utilization in general practice after HPV vaccination-A Danish nationwide register-based cohort study. PLoS One (2017) 0.75
Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types. Oncotarget (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Worldwide burden of cervical cancer in 2008. Ann Oncol (2011) 5.66
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA (2013) 3.06
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis (2009) 2.92
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis (2015) 2.48
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst (2015) 2.18
Validity of parent-reported vaccination status for adolescents aged 13-17 years: National Immunization Survey-Teen, 2008. Public Health Rep (2011) 1.71
Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer (2012) 1.69
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst (2016) 1.30
Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer (2013) 1.25
Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med (2011) 1.23
Role of Human Papillomavirus in Penile Carcinomas Worldwide. Eur Urol (2016) 1.07
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev (2014) 1.03
Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine (2013) 0.98
Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine (2014) 0.94
Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer (2014) 0.93
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J (2015) 0.91
Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther (2015) 0.90
HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust (2016) 0.84
Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females. JAMA Pediatr (2016) 0.83
How to best measure the effectiveness of male human papillomavirus vaccine programmes? Clin Microbiol Infect (2015) 0.83
Cervical cancer prevention in Australia: Planning for the future. Cancer Cytopathol (2015) 0.82
Juvenile recurrent respiratory papillomatosis: 10-year audit and Australian prevalence estimates. Laryngoscope (2016) 0.78
Discounting role in cost-effectiveness of HPV vaccination by Starkie Camejo et al. (Public Health Vol 129(7):989-92). Public Health (2015) 1.07
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA (2016) 0.76
Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. J Infect Dis (2017) 0.75